Surgical Technique and Efficacy Analysis of Extra-pseudocapsular Transnasal Transsphenoidal Surgery for Pituitary Microprolactinoma

Abstract

Objective

To elucidate the role of transsphenoidal surgery in the treatment of pituitary microprolactinoma.

Methods

The clinical data of 107 prolactinoma cases treated by extra-pseudocapsular transnasal transsphenoidal surgery (ETTS) for different indications in our department since 2011 was retrospectively analyzed.

Results

The most common indication was the ineffectiveness of oral medication (41.1%), followed by the personal willingness of the patient (35.5%), and 20.6% of the patients were young women with clear tumor boundaries. The pseudocapsule was not observed in 63 cases (58.9%), incomplete pseudocapsule was observed in 26 cases (24.3%), and complete pseudocapsule in 18 cases (16.8%). A total of 97 patients (90.7%) obtained 1-year post-operation remission. According to the relative location of the adenoma and pituitary gland on the MRI scan, 46 patients were classified into a central type, 59 a lateral type, and 2 a supra-pituitary type. Two patients developed hypogonadism, one patient developed hypocortisolism, and one patient developed post-operative hypothyroidism. Two patients were administrated with hormone replacement treatment, and the treatment was stopped within one week. There was no permanent hypopituitarism. Further investigation demonstrated that the adenoma types could affect the remission rates of hyperprolactinemia and gross total resection rate in microprolactinoma.

Conclusion

ETTS was an effective treatment for pituitary microprolactinomas. This could be the first choice for patients who presented enclosed adenoma on the MRI and were potentially curable in a preoperative evaluation. Maximal safe removal of the adenoma by ETTS with the aim to increase the sensitivity of the drugs was also recommended for patients with invasive dopamine agonist resistant prolactinomas and patients with difficulty in childbirth.

Keywords

pituitary microprolactinoma / extra-pseudocapsular transsphenoidal surgery / adenoma types / surgical technique / surgery indication

References

[1] VroonenL, DalyAF, BeckersA. Epidemiology and Management Challenges in Prolactinomas. Neuroendocrinology, 2019, 109(1): 20-27

[2] GieseS, Nasi-KordhishtiI, HoneggerJ. Outcomes of Transsphenoidal Microsurgery for Prolactinomas — A Contemporary Series of 162 Cases. Exp Clin Endocrinol Diabetes, 2021, 129(3): 163-171

[3] NomikosP, BuchfelderM, FahlbuschR. Current management of prolactinomas. J Neuro-oncol, 2001, 54(2): 139-150

[4] YanZ, LeiT. Hypogonadism in Male Patients with Pituitary Adenoma and Its Related Mechanism: A Review of Literature. Brain Sci, 2022, 12(6): 796

[5] WanX, YanZ, TanZ, et al.. MicroRNAs in Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology, 2022, 112(5): 417-426

[6] SalvatoriR. Surgical treatment of microprolactinomas: pros. Endocrine, 2014, 47(3): 725-729

[7] CaputoC, PriorD, InderWJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol, 2015, 3(11): 906-913

[8] BuchfelderM, ZhaoY, SchlafferSM. Surgery for Prolactinomas to Date. Neuroendocrinology, 2019, 109(1): 77-81

[9] JhoHD. Endoscopic transsphenoidal surgery. J Neurooncol, 2001, 54(2): 187-195

[10] HoneggerJ, Nasi-KordhishtiI, AboutahaN, et al.. Surgery for prolactinomas: a better choice?. Pituitary, 2020, 23(1): 45-51

[11] JethwaPR, PatelTD, HajartAF, et al.. Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States. World Neurosurg, 2016, 87: 65-76

[12] CasanuevaFF, MolitchME, SchlechteJA, et al.. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol, 2006, 65(2): 265-273

[13] KreutzerJ, BusleiR, WallaschofskiH, et al.. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol, 2008, 158(1): 11-18

[14] LuL, WanX, XuY, et al.. Classifying Pituitary Adenoma Invasiveness Based on Radiological, Surgical and Histological Features: A Retrospective Assessment of 903 Cases. J Clin Med, 2022, 11(9): 2464

[15] ChenJ, GuoX, MiaoZ, et al.. Extra-Pseudocapsular Transsphenoidal Surgery for Microprolactinoma in Women. J Clin Med, 2022, 11(13): 3920

[16] BuchfelderM, AdamsEF, KiesewetterF, et al.. Proliferation parameters for pituitary adenomas. Acta neurochir Suppl, 1996, 65: 18-21

[17] TampourlouM, TrifanescuR, PaluzziA, et al.. Therapy of endocrine disease: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol, 2016, 175(3): R89-96

[18] LosaM, MortiniP, BarzaghiR, et al.. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metabol, 2002, 87(7): 3180-3186

[19] OldfieldEH, VortmeyerAO. Development of a histological pseudocapsule and its use as a surgical capsule in the excision of pituitary tumors. J Neurosurg, 2006, 104(1): 7-19

[20] BuchfelderM, SchlafferSM, ZhaoY. The optimal surgical techniques for pituitary tumors. Best Pract Res Clin Endocrinol Metab, 2019, 33(2): 101299

[21] IkedaH, WatanabeK, TominagaT, et al.. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg, 2013, 115(9): 1621-1625